Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial

The LEADER Publication Committee on behalf of the LEADER Trial Investigators

Research output: Contribution to journalLetterpeer-review

16 Scopus citations
Original languageEnglish (US)
Pages (from-to)1605-1607
Number of pages3
JournalCirculation
Volume138
Issue number15
DOIs
StatePublished - 2018

Keywords

  • Diabetes mellitus
  • Liraglutide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this